{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4","upperLimit":"28","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"Cumulative incidence rate of treatment related mortality with relapse as a competing risk, assessed at 30 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"See Detailed Description\n\nrituximab: Given IV\n\ncyclosporine: Given orally\n\nfludarabine phosphate: Given IV\n\nmycophenolate mofetil: Given orally\n\nyttrium Y 90 ibritumomab tiuxetan: Given IV\n\nperipheral blood stem cell transplantation: Undergo transplantation\n\nallogeneic hematopoietic stem cell transplantation: Undergo transplantation\n\ntotal-body irradiation: Undergo TBI","id":"OG000","title":"Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"At day +100","title":"Treatment Related Mortality (TRM)","type":"PRIMARY","unitOfMeasure":"percent"}